The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
Tuesday, Jan. 14 Cleveland at Indiana, 7 p.m. Oklahoma City at Philadelphia, 7 p.m. Phoenix at Atlanta, 7:30 p.m. New Orleans at Chicago, 8 p.m. Sacramento at Milwaukee, 8 p.m. Denver at Dallas, 9:30 ...